CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial
MT Newswires Live
Jul 28
CSPC Pharmaceutical (HKG:1093) said its Phase 3 clinical trial of Ammoxetine Hydrochloride Enteric-coated Tablets met its primary endpoint in patients with depression, according to a Monday filing with the Hong Kong bourse.
The trial showed the drug significantly improved Montgomery-Åsberg Depression Rating Scale (MADRS) scores after eight weeks of treatment compared with placebo and was numerically superior to the active control.
HA1406 also demonstrated favorable trends across multiple secondary endpoints and a good safety profile, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.